Tetraphase's antibiotic fails late-stage study, shares plummet

(Reuters) - Tetraphase Pharmaceuticals Inc said on Tuesday its lead experimental antibiotic to treat serious infections did not meet the main goals in a late-stage study, sending its shares plunging more than 60 percent in after-market trading. The antibiotic, eravacycline, was being studied in a pivotal 1,205 patient study for the treatment of complicated urinary tract infections. Tetraphase s...